The Involvement of RIPK1 in Alopecia Areata

This study examines the similarities and differences in the pathogenesis of autoimmune conditions alopecia areata and vitiligo, highlighting shared features like immune cell involvement and cytokine pathways, while noting differing immune responses in skin and hair.

This study found that subcutaneous injection of a CXCL12 neutralizing antibody significantly promoted hair growth in androgenic alopecia and inhibited hair loss in alopecia areata in mouse models, suggesting its potential as a promising treatment for hair loss.

This study found that activating autophagy in hair follicle stem cells can promote hair growth by shifting their metabolism to glycolysis, while inhibiting it led to delayed hair cycle progression.

In this study using a mouse model and human data, researchers found that CD8+ T cells are central to driving alopecia areata, while regulatory T cells offer some protection, highlighting CD8+ T cells as key targets for future therapy development.

In this study, selective inhibition of JAK3 signaling effectively prevented and reversed alopecia areata in a mouse model, while JAK2 inhibitors did not restore hair growth.

This review explores the autoimmune hypothesis of alopecia areata and the possible genetic and melanogenesis-associated autoantigens, but reports no new clinical findings.

In this study, Nec-1s was found to promote hair growth and may target necroptosis and the Wnt/β-catenin pathway for potential treatment of hair loss.

This study found that activating autophagy with specific small molecules and drugs can stimulate hair growth by initiating the anagen phase in dormant hair follicles, suggesting a potential treatment for hair loss.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.